← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Global Health Uganda, Ltd
Kampala
$2,525,614
Total funding
2
Grants
Funding over time
peak $571.4K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,525,614 · 2
By mechanism
R01$2,164,774 · 1
R21$360,840 · 1
Investigators at Global Health Uganda, Ltd
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$464,236
R01 · FY2019 · HD
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$401,623
R01 · FY2020 · HD
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$390,950
R01 · FY2022 · HD
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$389,531
R01 · FY2023 · HD
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$386,000
R01 · FY2021 · HD
An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children$185,367
R21 · FY2021 · TW
An implementation toolkit for the use of hydroxyurea in the treatment of sickle cell aneamia in Ugandan children$175,473
R21 · FY2022 · TW
Burden and Risk of Neurological and Cognitive Impairment in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II)$132,434
R01 · FY2023 · HD